What it sells
Smart gels for local drug delivery to the gut
Business model breakdown
Buyer: who owns the budget?
UnverifiedPharma partners and investors (site has an "Investors & Partners" line).
Economics: what it saves and how it charges
UnverifiedClinical-stage biopharma; value is from developing/licensing localized GI drug-delivery therapies, no product revenue stated.
Distribution: how it reaches customers
UnverifiedPartnering/licensing and investor outreach via contact email.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Winter 2019 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.